Global Down Syndrome

Fall 2015

Issue link: https://viewer.e-digitaledition.com/i/618504

Contents of this Issue

Navigation

Page 7 of 31

EVEN THOUGH THE link between Alzheimer's disease and Down syndrome is well established, most researchers focus exclusively on either Down syndrome or on Alzheimer's disease development in typical, elderly populations. In 2012, the Global Down Syndrome Foundation and the national Alzheimer's Association made history when they held the first workshop devoted to discussing Alzheimer's disease in patients with Down syndrome. As evidenced by the growing number of workshops that have taken place since that initial gathering, scientific and medical communities have increasingly come together to study the link, which may hold the key to preventing Alzheimer's disease in both at-risk and typical populations. A JOINING OF COLLECTIVE EXPERTISE The Global Down Syndrome Foundation and the Alzheimer's Association held the most recent workshop devoted to Alzheimer's disease and Down syndrome in May 2015. The effort was supported by several organizations, including the LuMind Research Down Syndrome Foundation, the Linda Crnic Institute for Down Syndrome, and the Jerome Lejeune Foundation, and included notable experts, such as Michael S. Rafii, M.D., Ph.D., Clinical Director of the University of California, San Diego's Down Syndrome Center for Research and Treatment; Marwan Sabbagh, M.D., F.A.A.N., Director of the Memory Disorders Center and Professor of Neurology at Barrow Neurological Institute; and Huntington Potter, Ph.D., Director of Alzheimer's Research at the Crnic Institute. Representatives from two National Institutes of Health (NIH) organizations — the National Institute on Aging (NIA) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) — also attended. "The main advantage of workshops is that they bring new ideas from different people into one room so we can collectively determine how to best approach them," Dr. Potter said. "During this workshop, for example, several participating organizations agreed to share their pathology samples. This has resulted in a collective application to the NIH to collect blood samples and other tissues so we can study the natural history of Alzheimer's disease in people with Down syndrome." The increasing support from the NIH also means much-needed additional funding for new research projects. In 2015, the NIA and NICHD announced a $5 million per year, multiple-year research grant opportunity to help better understand Alzheimer's disease progression in adults with Down syndrome through identification of biomarkers, changes detectable through blood tests, and imaging studies that signal Alzheimer's disease development. This exciting advance may help put an end to the lack of funding facing Down syndrome research. UNDERSTANDING ALZHEIMER'S DISEASE PATHOLOGY In both people with Down syndrome and typical populations, Alzheimer's disease begins developing as many as 20 years before clinical symptoms appear. Starting drug treatment earlier may help prevent dementia, but to know when to begin treatment, researchers need an indication — either through a biomarker in the blood or an imaging biomarker in the brain — that a person will develop Alzheimer's disease. At the workshop, several roundtables were devoted to the Down Syndrome Biomarker Initiative, a project that launched in 2013 and is structured similarly to the Alzheimer's Disease Neuroimaging Initiative, a 10-year CONTINUED ON PAGE 10 A GROWING NUMBER OF NATIONAL AND INTERNATIONAL ORGANIZATIONS HAVE RECOGNIZED THE NEED FOR UNIFIED RESEARCH EFFORTS IN THE AREAS OF ALZHEIMER'S DISEASE AND DOWN SYNDROME. LEARN HOW THEIR TEAMWORK IS SPURRING PROGRESS TOWARD A SHARED GOAL OF PREVENTING ALZHEIMER'S DISEASE-RELATED DEMENTIA. Collaborating on Alzheimer's and Down Syndrome Research FALL2015 DOWN SYNDROME WORLD 8

Articles in this issue

Archives of this issue

view archives of Global Down Syndrome - Fall 2015